Eikon tries to follow Aktis
After Aktis's $318m flotation Eikon is a bigger proposition.
A second shot at PARP1 from Eikon
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
Venture cash funds first human trials
Private company trial initiations stand out in the latest week’s disclosures.
